According to the new market research report “High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User – Global Forecast to 2022“, published by MarketsandMarkets™,The global high-content screening market is expected to reach USD 909.0 Million by 2022 from USD 557.1 Million in 2017, at a CAGR of 10.3%.
Get 10% Free Customization @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=42710391
The need for cost containment in pharma R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.
High-content screening (HCS) is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
In 2016, the instruments segment accounted for the largest share in the HCS market. The large share of this segment is attributed to advanced automation techniques and high prices of HCS instruments. The cell imaging and analysis systems sub-segment accounted for the largest share of the HCS instruments market and is expected to further dominate the market by 2022.
Browse and in-depth TOC on “High Content Screening Market”
138 – Tables
42 – Figures
166 – Pages
For Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=42710391
Primary and Secondary Screening
The major users of HCS for primary and secondary screening are pharmaceutical and biotechnology companies and CROs involved in the drug discovery process. In recent years, the market has witnessed significant developments involving major players and prominent research institutes focusing on the use of HCS in screening applications. In secondary screening, HCS is used in qualitative assays to exclude the compounds with unintended modes of action.
Target Identification and Validation
Target identification and validation is the initial step in the drug discovery process. The benefits of high-content screening are especially relevant in drug discovery. Currently, late-stage failure during drug development can result in significant financial losses for companies. To eliminate this possibility, detailed insights are essential into how a drug or compound acts in a functional context on a cellular pathway. This results in more information and confidence in both hit selection as well as safety & efficacy, prior to lead candidate selection. Thus, target identification is a vital step in the drug discovery process.
The prominent players in the global high-content screening market are GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.). Product launches was the key growth strategy adopted by market players between 2014 and 2017. Companies also aim to differentiate themselves in the highly competitive global high-content screening market by expanding their product portfolios in accordance with industry trends and client needs.
